Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Reblozyl (luspatercept by Year
Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. sales ($M) ($M)
Merck Reblozyl (luspatercept: $432M in FY2025, up 42.6% from a year earlier.
Where the FY2025 figure comes from
“|| Alliance Revenue – Reblozyl (3) | 525 | 371 | 41 | 432 | 303 | 42 | 93 | 68 | 37”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 432 | +42.6% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 303 | +80.4% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 168 | +36.6% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 123 | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 0 | – | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 0 | – | Form 10-K (filed 2023-02-24) ↗ |
Breakdown
What makes up reblozyl (luspatercept
Cite this data
StockData. (2026). Merck Reblozyl (luspatercept ($M), annual FY2020–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-reblozyl-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.